Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans

Hepatology

Volumn 60, Issue 4, 2014, Pages 1291-1301

  Ladep, Nimzing G ^a   Dona, Anthony C ^a   Lewis, Matthew R ^a   Crossey, Mary M E ^a   Lemoine, Maud ^a,b   Okeke, Edith ^c   Shimakawa, Yusuke ^b   Duguru, Mary ^c   Njai, Harr F ^b   Fye, Haddy K S ^b   Taal, Makie ^d   Chetwood, John ^a   Kasstan, Ben ^a   Khan, Shahid A ^a   Garside, Deborah A ^a   Wijeyesekera, Anisha ^a   Thillainayagam, Andrew V ^a   Banwat, Edmund ^c   Thursz, Mark R ^a   Nicholson, Jeremy K ^a   Njie, Ramou ^b   Holmes, Elaine ^a   Taylor Robinson, Simon D ^a   more..

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Medical Research Council The Gambia Unit Fajara   (Gambia)

^c Royal Victoria Teaching Hospital Gambia   (Gambia)

^d Royal Victoria Teaching Hospital   (Gambia)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYLNICOTINAMIDE; 2 OXOGLUTARIC ACID; ACETYLCARNITINE; AMINO ACID; CHOLINE; CREATINE; DIMETHYLGLYCINE; GALACTOSE; INDOLEACETIC ACID; INOSINE; METHIONINE; N ACETYLATED AMINO ACID; UNCLASSIFIED DRUG; ALPHA FETOPROTEIN; ALPHA-KETOGLUTARIC ACID; N(1)-METHYLNICOTINAMIDE; NICOTINAMIDE; SARCOSINE; TUMOR MARKER;

ADULT; AFRICA; AGED; AREA UNDER THE CURVE; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GAMBIAN; HEALTH PROGRAM; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; METABOLISM; NIGERIAN; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TASK PERFORMANCE; TRAINING; URINALYSIS; URINARY METABOLISM; VALIDATION STUDY; WEST AFRICAN; ADOLESCENT; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS; MIDDLE AGED; REPRODUCIBILITY; URINE; VERY ELDERLY; YOUNG ADULT;

ACETYLCARNITINE; ADOLESCENT; ADULT; AFRICA, WESTERN; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHOLINE; CREATINE; FEMALE; HUMANS; KETOGLUTARIC ACIDS; LIVER NEOPLASMS; MALE; METHIONINE; MIDDLE AGED; NIACINAMIDE; PHENOTYPE; REPRODUCIBILITY OF RESULTS; SARCOSINE; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84927760587     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27264     Document Type: Article

References (38)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-3044.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. J Gastrointestin Liver Dis 2010;19:311-317.
4. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002;37:806-813.
5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-2576.
6. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-468.
7. El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37(Suppl. 2):S88-S94.
8. Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127(5 Suppl. 1):S108-S112.
9. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res 2007;6:2605-2614.
10. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping in clinical and surgical environments. Nature 2012;491:384-392.
11. Cao H, Huang H, Xu W, Chen D, Yu J, Li J, et al. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. Anal Chim Acta 2011;691:68-75.
12. Chen F, Xue J, Zhou L, Wu S, Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem 2011;401:1899-1904.
13. Chen T, Xie G, Wang X, Fan J, Qiu Y, Zheng X, et al. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Mol Cell Proteomics 2011;10:M110.
14. Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Mol Biosyst 2009;5:868-876.
15. Zhou L, Wang Q, Yin P, Xing W, Wu Z, Chen S, et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases. Anal Bioanal Chem 2012;403:203-213.
16. Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 2009;648:98-104.
17. Ye G, Zhu B, Yao Z, Yin P, Lu X, Kong H, et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. J Proteome Res 2012;11:4361-4372.
18. Wang X, Zhang A, Sun H, Yan G, Han Y, Ye Y. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. Clin Chim Acta 2013;418:86-90.
19. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
20. Shariff MI, Ladep NG, Cox IJ, Williams HR, Okeke E, Malu A, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res 2010;9:1096-1103.
21. Shariff MI, Gomaa AI, Cox IJ, Patel M, Williams HR, Crossey MM, et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an egyptian population: a validation study. J Proteome Res 2011;10:1828-1836.
22. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-943.
23. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
24. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007;2:2692-2703.
25. Bollard ME, Keun HC, Beckonert O, Ebbels TM, Antti H, Nicholls AW, et al. Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. Toxicol Appl Pharmacol 2005;204:135-151.
26. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995;67:793-811.
27. Cloarec O, Dumas ME, Craig A, Barton RH, Trygg J, Hudson J, et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. Anal Chem 2005;77:1282-1289.
28. Polanski M, Anderson NL. A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007;1:1-48.
29. Macuks R, Baidekalna I, Donina S. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case-control study. Asian Pac J Cancer Prev 2012;13:4695-4698.
30. Dong X, Wang G, Zhang G, Ni Z, Suo J, Cui J, et al. The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer. Diagn Pathol 2013;8:45.
31. Shariff MI, Ladep NG, Cox IJ, Williams HR, Okeke E, Malu A, et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. J Proteome Res 2010;9:1096-1103.
32. Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Ketone body utilization drives tumor growth and metastasis. Cell Cycle 2012;11:3964-3971.
33. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer 2011;11:835-848.
34. Bell JD, Bhakoo KK. Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours. NMR Biomed 1998;11:354-359.
35. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308.
36. Costello LC, Franklin RB. The genetic/metabolic transformation concept of carcinogenesis. Cancer Metastasis Rev 2012;31:123-130.
37. Pahor M, Manini T, Cesari M. Sarcopenia: clinical evaluation, biological markers and other evaluation tools. J Nutr Health Aging 2009;13:724-728.
38. Heinzmann SS, Merrifield CA, Rezzi S, Kochhar S, Lindon JC, Holmes E, et al. Stability and robustness of human metabolic phenotypes in response to sequential food challenges. J Proteome Res 2012;11:643-655.